- Home
- SGLT-2 Inhibitors - Another Piece of the Puzzle in Heart Failure
SGLT-2 Inhibitors - Another Piece of the Puzzle in Heart Failure
- Heart Failure
Available Credit:
- 1.00
Course Published On:
Course Expiry Date:
Overview
Presented, and recorded, at the ESC in Barcelona, this unique broadcast, ‘SGLT-2 Inhibitors - Another Piece of the Puzzle in Heart Failure’, is centred around the presentation of the latest SGLT-2 inhibition data and how this translates to the treatment of Heart Failure patients.
Radcliffe Medical Education is delighted to introduce the globally renowned faculty. Chaired by Prof Scott Solomon (Boston, US), this session brings together a leading international faculty of Prof John McMurray (Glasgow, UK), Prof Carolyn Lam (Singapore, SG) and Dr Muthiah Vaduganathan (Boston, US) to assess the latest data for SGLT2 inhibitors in heart failure (HF) and how to apply it in real-world practice.
Support Statement
This satellite symposium is supported by an unrestricted educational grant from AstraZeneca who had no involvement in the creation of the content.
Disclosure
In compliance with EBAC guidelines, all speakers/chairpersons participating in this programme have disclosed or indicated potential conflicts of interest which might cause a bias in the presentations. The Organising Committee/Course Director is responsible for ensuring that all potential conflicts of interest relevant to the event are declared to the audience prior to the CME activities.
Terms & Conditions
Radcliffe Education requires contributors to our CME programmes to disclose any relevant financial relationships that have occurred within the past 12 months that could create a conflict of interest. These will be identified in the faculty section if applicable.
The session, ‘SGLT-2 Inhibitors - Another Piece of the Puzzle in Heart Failure’ is accredited by the European Board for Accreditation in Cardiology (EBAC) for 1 hour of external CME credits.
Each participant should claim only those hours of credit that have actually been spent in the educational activity. EBAC works according to the quality standards of the European Accreditation Council for Continuing Medical Education (EACCME), which is an institution of the European Union of Medical Specialists (UEMS).
Through an agreement between the European Board for Accreditation in Cardiology and the American Medical Association, physicians may convert EBAC External CME credits to AMA PRA Category 1 Credits™. Information on the process to convert EBAC credit to AMA credit can be found on the AMA website.
Instructions to Participants
There is no fee for taking part in this online learning activity.
Activities are designed to be completed within 60 minutes and must be completed by the registered user. Physicians should only claim credits for time spent on the activity. To successfully earn credit, participants must complete the activity in full in the indicated time frame.
To complete the course and claim certification participants must:
- Read the course outline information supplied and complete pre-test questions if supplied prior to starting the activity. Users must read and study the activity in its entirety before completing the post-test questions.
- Your results will be automatically saved and if a pass score is achieved (where applicable), you may be eligible to claim credit for the activity and receive a certificate of completion.
Target Audience
- Global Cardiologists
- Heart Failure Specialists
- Primary Care Physicians
- Nurses
- Pharmacists
Learning Objectives
Upon completion of this activity, participants will be able to:
- Recall the results of key trials in HFmrEF in different patients' sub-groups
- Describe how SGLT-2 inhibitors can be used across the range of LVEF
- Apply emerging diagnostic approaches for HFpEF and HFmrEF
- Implement best-practice strategies across the range of LVEF
SGLT2 Inhibitors in HFpEF: Light at the End of the Tunnel
Duration: 15 min
Speakers: Scott Solomon (Brigham and Women's Hospital / Harvard Medical School, Boston, US)
SGLT2 Inhibitors Across the Spectrum of Heart Failure
Duration: 10 min
Practical Considerations For Treating HF With Mildly Reduced and Preserved EF
Duration: 10 min
Speakers: Carolyn Lam (National Heart Centre Singapore Duke-NUS, Singapore, Singapore, SG)
Implementing Best Practices Across the Spectrum of Heart Failure
Duration: 10 min
Discussion
Duration: 15 min
Speakers: Scott Solomon (Brigham and Women's Hospital, Boston, US / Harvard Medical School, Boston, US) John JV McMurray (Institute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, UK) Carolyn Lam (National Heart Centre Singapore Duke-NUS, Singapore, Singapore, SG) Muthiah Vaduganathan (Brigham and Women's Hospital Heart and Vascular Center and Harvard Medical School, Boston, Boston, US)
Related Courses
- 1.00
Published:
Learning objectives
- Define residual inflammatory risk (RIR) and explain why cardiovascular events continue to occur in patients despite optimal lipid-lowering and antihypertensive therapies
- Describe the pathophysiological role of inflammation in atherosclerosis, myocardial infarction, heart failure and chronic kidney disease
- Identify patients at increased cardiovascular risk due to elevated inflammatory markers, particularly high-sensitivity C-reactive protein (hsCRP)
- Interpret the clinical significance of hsCRP and other inflammatory biomarkers in primary and secondary prevention settings, in alignment with current evidence and guideline recommendations
- Assess clinician practices, barriers and strategies for integrating inflammatory risk assessment and management
- Apply key takeaways to inform future risk assessment and treatment decisions in patients with or at risk for cardiovascular disease
- 1.00
Published:
Learning objectives
- Summarise the long-term burden and current unmet needs for patients with HF and EF ≥40%
- Recall data on new therapies being evaluated in the HFmr/pEF population, including data from the AHA 2024 annual congress
- Describe how non-steroidal MRAs differ in their mechanism of action and elicit their benefits in HF
- 1.00
Published:
Learning objectives
- Describe the current limitations of HFmrEF/HFpEF GDMT in advanced patients
- Select appropriate patients for advanced medical therapy
- Recall recent trial data for novel therapeutic approaches
- Use expert guidance to develop an evidence-based approach to managing advanced HFmrEF/HFpEF
- 1.25
Published:
Learning objectives
- To identify high-risk patient features indicative of worsening Heart Failure (HF)
- Name validated tools for serial prognostic assessment and risk stratification
- Adopt the use of appropriate assessment tools during patient follow-up
- Recall rates of recurrent HF events and their associated healthcare costs in worsening HF patients
- Recall the clinical benefit of emerging treatments targeted to treating worsening HF
- Initiate available treatment for the tailored management of worsening HF
- 1.00
Published:
Learning objectives
- Understand the nature of amyloidosis and its effects on various organs, particularly the heart
- Distinguish between light-chain (AL) amyloidosis, wild type TTR amyloidosis and hereditary TTR amyloidosis in terms of their clinical manifestations and their different treatments
- Recognise the novel challenges of managing heart failure in cardiac amyloidosis, including both medical management and the role of devices
- Understand the critically important interaction between haematologists and cardiologists in the therapy of AL amyloidosis
- Develop an understanding of novel therapies currently in clinical trials of TTR and AL amyloidosis
- Identify their own roles and responsibilities in the management TTR and AL amyloidosis as part of a multidisciplinary team
- 0.50
Published:
Learning objectives
- Recall recent trial data for novel disease modifying therapy in HCM
- Describe the evolving guideline directed approach to managing HCM
- Develop an expert-led approach to implementing novel therapy in clinical practice
- Not accredited
Published:
Learning objectives
- Recall guideline recommendations for the use of NT-proBNP in heart failure
- Describe current practices in heart failure diagnosis and the impact on treatment outcomes
- Develop an optimised approach to the timely diagnosis and management of heart failure
- 2.00
Published:
Learning objectives
- Recall clinical evidence and guidelines for the management of CKD patients without diabetes
- Describe current gaps and barriers in evidence-based management for CKD without diabetes
- Apply evidence based-management strategies to a case study
- Use expert-led guidance to develop an optimal management approach to CKD patients without diabetes